Healthcare resources are finite and rationing is common. Fair distribution assumes that equals are treated equally and unequals are treated unequally, based on morally relevant differences such as the needs of and likely benefits to the patients. Applying these considerations in practice is complex. A case is described to illustrate the ethical issues raised by patients’ requests to pay for an expensive drug treatment.
New B.The rationing agenda in the NHS. BMJ1996; 312: 1593-1601.
2.
Ferguson JS, Summerhayes M, Masters S, Schey S, Smith IE.New treatments for advanced cancer: an approach to prioritization [comment]. Br J Cancer2000; 83: 1268-1273.
3.
Foy R, So J, Rous E, Scarffe JH.Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold [comment]. BMJ1999; 318: 456-459.
4.
Scott SN, Lees A.Developing a prioritisation framework: experiences from a Scottish Health Authority. Health Expect2001; 4: 10-17.
5.
Laupacis A.Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?Can Med Assoc J2002; 166: 44-47.
6.
Bochner F, Martin ED, Burgess NG, Somogyi AA, Misan GM.How can hospitals ration drugs? Drug rationing in a teaching hospital: a method to assign priorities. Drug Committee of the Royal Adelaide Hospital. BMJ1994; 308: 901-905.
7.
Glass A.The Oregon Health Plan: development and implementation of an innovative method of delivery of health care services to the medically indigent. Cancer1998; 82: 1995-1999.
8.
Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Muller CB, Rarick MU, Regan DH, Browman GP, Gordan MS.Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol2002; 20: 4083-4107.
9.
Bottomley A, Thomas R, Van Steen K, Flechtner H, Djulbegovic B.Erythropoietin improves quality of life - a response. Lancet Oncol2002; 3: 527-527.
10.
Littlewood TJ, Cella D, Nortier JW.Erythropoietin improves quality of life. Lancet Oncol2002; 3: 459-460.
11.
Anonymous. Non-benefits: Eprex® (erythropoeitin). Pharmacare Newslett 21 March 2001: 4-5.
12.
Holm S.The second phase of priority setting. Goodbye to the simple solutions: the second phase of priority setting in health care. BMJ1998; 317: 1000-1002.
13.
Daniels N, Sabin J.Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff1997; 26: 303-350.
14.
Wight J, Richards M.Very high cost treatment for a single individual - a case report. J Public Health Med2003; 25: 4-7.
15.
Harris J.Justice and equal opportunities in health care. Bioethics1999; 13: 392-404.
16.
Jacobson PD, Asch S, Glassman PA, Model KE, Hernandez JB.Defining and implementing medical necessity in Washington State and Oregon. Inquiry1997; 34: 143-154.
17.
Kappel K, Sandoe P.QALYs, age and fairness. Bioethics1992; 6: 297-316.
18.
Kearney N, Miller M, Paul J, Smith K.Oncology healthcare professionals’ attitudes toward elderly people. Ann Oncol2000; 11: 599-601.
19.
Zweibel NR, Cassel CK, Karrison T.Public attitudes about the use of chronological age as a criterion for allocating health care resources. Gerontologist1993; 33: 74-80.
20.
Goodman M.Ethical issues in health care rationing. Nurs Manag (Harrow)1998; 5: 29-33.
21.
Holm S, Liss PE, Norheim OF.Access to health care in the Scandinavian countries: ethical aspects. Health Care Anal1999; 7: 321-330.
22.
Ham C.Tragic choices in health care: lessons from the Child B case. BMJ1999; 319: 1258-1261.
23.
Montandon M.A defense of visible health care rationing. Princet J Bioeth2001; 4: 64-78.
